1. Home
  2. DLPN vs BLRX Comparison

DLPN vs BLRX Comparison

Compare DLPN & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dolphin Entertainment Inc.

DLPN

Dolphin Entertainment Inc.

HOLD

Current Price

$1.58

Market Cap

21.8M

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

N/A

Current Price

$3.17

Market Cap

17.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DLPN
BLRX
Founded
1996
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.8M
17.1M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
DLPN
BLRX
Price
$1.58
$3.17
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
38.9K
28.4K
Earning Date
11-12-2025
11-24-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$53,371,115.00
$12,735,000.00
Revenue This Year
$10.62
N/A
Revenue Next Year
$13.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.86
N/A
52 Week Low
$0.75
$2.30
52 Week High
$1.88
$14.70

Technical Indicators

Market Signals
Indicator
DLPN
BLRX
Relative Strength Index (RSI) 48.08 46.97
Support Level $1.50 $3.16
Resistance Level $1.70 $3.43
Average True Range (ATR) 0.08 0.22
MACD -0.01 0.01
Stochastic Oscillator 49.52 26.03

Price Performance

Historical Comparison
DLPN
BLRX

About DLPN Dolphin Entertainment Inc.

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: